Vivimed Labs is currently trading at Rs. 106.10, up by 5.05 points or 5.00% from its previous closing of Rs. 101.05 on the BSE.
The scrip opened at Rs. 96.00 and has touched a high and low of Rs. 106.10 and Rs. 96.00 respectively. So far 197627 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 403.65 on 10-Sep-2012 and a 52 week low of Rs. 101.05 on 31-Jul-2013.
Last one week high and low of the scrip stood at Rs. 216.50 and Rs. 101.05 respectively. The current market cap of the company is Rs. 170.41 crore.
The promoters holding in the company stood at 39.83% while Institutions and Non-Institutions held 29.87% and 30.30% respectively.
Vivimed Labs has acquired Actavis Pharma Manufacturing’s (APMPL) solid oral dosage facility in Alathur, Tamil Nadu for Rs 122 crore. The facility, which Vivimed acquired from APMPL’s parent Actavis Holding Asia BV, has already received the US Food and Drug Administration (US FDA) approval.
Along with the facility, the company has also acquired two commercially valuable and marketable Abbreviated New Drug Applications (ANDAs) which will allow the company to generate additional revenues.
Vivimed Labs’s manufacturing unit is located at Bidar, Karnataka, where it was originally engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs) and bulk drugs like Ibuprofen etc.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1681.20 |
| Dr. Reddys Lab | 1227.10 |
| Cipla | 1229.10 |
| Zydus Lifesciences | 932.05 |
| Lupin | 2333.50 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: